SUMMARY -Diabetes is one of the leading public health problems worldwide. Diabetic macular edema (DME) is the main cause of vision loss in patients with diabetes. Ideal metabolic control of diabetes is the primary goal of treatment and the basic way of preventing and stopping the progression of DME. Although laser photocoagulation has been the standard treatment of DME for nearly three decades, superior outcomes can be achieved with novel, intravitreal anti-VEGF and steroid therapy. Novel treatment option for DME depends on visual acuity and location/extent of macular thickening based on optical coherence tomography scans. According to the International Clinical Classifi cation Scale, DME is divided into no center-involving DME and center-involving DME (CI-DME). New guidelines recommend intravitreal treatment as the treatment of choice for patients with CI-DME and moderate visual impairment. Patients with no CI-DME and mild visual impairment should be treated with modifi ed ETDRS laser photocoagulation and closely observed. Vitrectomy is the treatment of choice for patients with a tractional component of DME. Nowadays, traditional treatment goal of preventing blindness in patients with DME has been changed by the new goal aiming to restore impaired vision, prevent further vision loss and improve visual function. Th erefore, many trials addressing this new concept have been underway worldwide.
Introduction
Diabetes is the most common endocrine disease in developed countries and one of the most common non-communicable diseases globally, estimated to have aff ected more than 415 million people in 2015 and projected to aff ect 642 million by 2040 1 . Th e existing burden of disease, high prevalence and incidence, life course characterized by development of chronic complications, decreased quality of life and increased cost of health care make diabetes one of the leading public health problems worldwide. Diabetes deaths have almost doubled in the last two decades worldwide 2 . In 2012, diabetes directly caused 1.5 million deaths 3 , while as much as 5 million deaths were attributable to diabetes, accounting for 14.5% of global allcause mortality among adults 1 . High blood glucose is the 3 rd most important risk factor for premature mortality 4 , and diabetes is the 9 th leading cause of disability worldwide 5 . In the last decades, one of the greatest increases in years lived with disability (YLDs) was observed in diabetes, especially in diabetes complications, among which the highest increase of 36.7% was observed for vision loss due to diabetes 5 . In diabetes, vision loss is most commonly the result of diabetic retinopathy (DR) and diabetic macular edema (DME) 6 , frequent diabetes complications present in as much as 34.6% and 6.81% of patients with diabetes, respective-ly. DME, but not DR per se, is nowadays the main cause of vision loss in patients with diabetes 7 . Although estimations may diff er upon the diagnostics used 8 , studies revealed up to 21 million DME and 28 million vision threatening DR 7 . Diabetic macular edema is a special form of diabetic retinopathy, a highly specifi c microvascular complication of diabetes on the eyes. DME is thickening of the retina within two diameters of the optic nerve from the center of the macula, functionally the most important part of the eye 9 . It is caused by breakdown of the blood-retinal barrier, abnormal microvascular permeability and consequent leakage of fl uid and plasma constituents into the layers of the macula 10 . Structural changes of DME are characterized by the accumulation of liquid and hard exudates in the outer plexiform and inner nuclear layers of the macula and formation of fl uid-fi lled cystoid spaces.
Morphologically, macular edema may be focal and diff use. Focal edema is well-circumscribed macular thickening associated with complete or incomplete rings of hard exudates caused by leakage from one or more individual microaneurysms. Diff use edema is diff use macular thickening caused by widespread leakage from dilated and abnormally permeable capillaries. Unlike focal edema, diff use edema is less surrounded by hard lipid exudates, but more often due to widespread leakage by marked damage to macular architecture and development of cystoid spaces. Especially signifi cant edema, because of its impact on the central vision, is edema located within 500 μm of the center of the macula (clinically signifi cant macular edema).
Risk Factors for DME
Diabetic macular edema develops and progresses as a result of the interaction of diff erent non-modifi able and modifi able risk factors.
Diabetes duration is the most important non-modifi able risk factor directly associated with the incidence and prevalence of DME in patients with both types of diabetes. Th e Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) in the USA found that 20% of patients with type 1 diabetes and 14%-25% of patients with type 2 diabetes developed DME over a 10-year follow up period 11 . Data from the 25-year follow up of the WESDR cohort found that the cumulative incidence of DME was 29% 12, 13 . Although the cumulative incidence of DME increased with duration of diabetes, the correlation was not linear, presumably due to the increased competing risk of death. Hyperglycemia is the strongest modifi able risk factor for the development and progression of DR and DME. Th e Diabetes Control and Complications Trial (DCCT) in type 1 diabetes and the United Kingdom Prospective Diabetes Study (UKPDS) in type 2 diabetes found that tighter control of glycemia (HbA 1 c ≤7%) signifi cantly reduced the risk of development and progression of DR, DME, vitreal hemorrhage and need for laser treatment, as well as the risk of blindness 14, 15 . Th e DCCT also found that intensive glycemic control was associated with 46% reduction in the incidence of DME at the end of the trial and 58% reduction 4 years later compared with those in the conventional group 16 . Hypertension is also an important modifi able risk factor for DME 12, 13 . Each 10-mm Hg increase in systolic blood pressure was associated with an approximately 15% additional risk of DME 17 . In the UKPDS, patients with hypertension with tight blood pressure control had a 34% reduction in the rate of progression of DME and 47% reduction in deterioration of visual acuity (VA) 18 . Some clinical trials also showed that specifi c blood pressure-lowering medications that target the renin-angiotensin system had additional benefi cial eff ects on DR and DME, independently of their hypotensive actions 19, 20 . Dyslipidemia has a signifi cant role in the pathogenesis of DME; some studies report that serum lipids were independently associated with DME 21 . Th e Fenofi brate Intervention and Event Lowering in Diabetes (FIELD) study showed that fenofi brate reduced the frequency of laser treatment for DME by 31% in type 2 diabetes 22 . Notably, the fi nding in the FIELD study appeared not only to be attributable to measurable changes in lipid profi le, suggesting that other as yet unknown mechanisms could contribute to the protective eff ect of fenofi brate 22 . Other non-modifi able and modifi able risk factors are puberty, pregnancy, genetic factors, nephropathy, obesity 23 and smoking.
Traditional Treatment of DME
Ideal metabolic control of diabetes, assuming strict control of well-known modifi able risk factors of hy-perglycemia, hypertension, dyslipidemia and others, is the primary goal of treatment and the basic way of preventing and stopping the progression of DME 14, 15, 22, 24, 25 . Laser photocoagulation has been the primary treatment for DME since the early 1980s. Th e role of laser in preventing visual loss and blindness due to DME was established in 1970s-1980s by two large studies, the Diabetic Retinopathy Study (DRS) 26 and the Early Treatment Diabetic Retinopathy Study (ETDRS) 27, 28 . Laser photocoagulation was performed as focal treatment of microaneurysms and other areas of focal leakage with a 50-100 μm spot size to obtain defi nite whitening around the area of leakage, or as grid treatment of abnormally permeable capillaries and other areas of diff use leakage within two disc diameters of the center using spot sizes of 50-200 μm and a space of one burn width apart. Th e ETDRS demonstrated that photocoagulation reduced the risk of moderate vision loss caused by DME in about 50% of the eyes, in only 3% of eyes this therapy led to improvement of VA, and in the rest VA unfortunately remained poor due to persistence of macular edema 27, 28 . Th e ETDRS also indicated that laser treatment was neither ideal therapy nor possible in every single eye with DME. Th e potential complications of macular laser include laser scar expansion, paracentral scotomata, elevation of central visual fi eld thresholds, secondary choroidal neovascularization and subretinal fibrosis 29, 30 .
Novel Treatment Options for DME
Nowadays, the DRCR Network group recommends a modifi ed ETDRS focal/grid laser regimen as follows: all leaking microaneurysms 500 to 3000 μm from fovea should be treated directly with 50 μm spot size, duration 0.05-0.1 s and intensity to achieve grayish reaction; grid treatment should be performed to areas of retinal thickening from 500 to 3000 μm superiorly and inferiorly and to 3500 μm temporally with a space of two burns width apart 31 . Subthreshold micropulse diode laser photocoagulation is a treatment that theoretically avoids damaging the inner neurosensory retina, thereby reducing potential complications such as paracentral scotomata and enlargement of post-treatment scars. Th is technique was fi rst described in the late 1990s and since then there has been some randomized controlled trials (RCTs) comparing this technique to modifi ed ET-DRS laser treatment 32, 33 . In their trial, Vujosevic et al. found improvement of central retinal sensitivity in the micropulse group, but its deterioration in the modifi ed ETDRS group 34 . Micropulse laser thus may off er a new, less aggressive laser approach in the treatment of clinically signifi cant macular edema.
Corticosteroids are potent anti-infl ammatory agents that can counteract many of the pathological processes thought to play a role in the development of macular edema. Th ey prevent leukocyte migration, reduce fibrin deposition, stabilize endothelial cell tight junctions, and inhibit synthesis of vascular endothelial growth factor (VEGF), prostaglandins and proinfl ammatory cytokines 35, 36 . Th e fi rst reports on the use of intravitreal corticosteroid injection for DME were published in [2001] [2002] 37,38 , suggesting that intravitreal triamcinolone (IVTA) is potentially an eff ective treatment for DME. Th is treatment has gained widespread use as an off -label agent in a number of ocular diseases, including DME, most commonly at a dose of 4 mg of triamcinolone acetonide (Kenalog®; BristolMyers Squibb, Princeton, NJ, USA), despite the lack of data from a controlled study demonstrating its safety and effi cacy. Recently, the DRCR.net found that IVTA had best eff ect on VA improvement within 4 months of the application and that this eff ect was transient 39 . A longer-lasting and doubling eff ect on VA was achieved only by using the IVTA plus focal/grid laser treatment 40 . Th e IVTA treatment is considerably limited by adverse events, high incidence of cataract formation and raised intraocular pressure 40 , and difficulty in delivering eff ective doses of therapeutic agents into the vitreous cavity. In recent years, development of a sustained-release intravitreal dexamethasone implant (Ozurdex®, Allergan Inc., Irvine, CA, USA) has allowed more controlled delivery of the drug with a potentially lower rate of adverse events 41 . In a study evaluating the safety and effi cacy of dexamethasone implant versus observation in the eyes with persistent DME, treatment with intravitreal dexamethasone implant was well-tolerated and produced signifi cant improvements in VA, central retinal thickness (CRT) and fl uorescein leakage compared with observation 42 . In 2014, the US Food and Drug Administration (FDA) approved Ozurdex (dexamethasone intravitreal implant) for use in adult patients with DME who have an artifi cial lens implant or are scheduled for cataract surgery. Th is makes Ozurdex the fi rst corticosteroid approved for use in certain DME patients.
Another novel treatment approach, available for less than a decade, is the use of intravitreal therapies targeting vascular endothelial grown factor (VEGF) 43 , the most potent known promoter of vascular permeability 44 . Clinical studies have established that VEGF levels are elevated in eyes with DME 45 and preclinical studies found correlation between increased VEGF level and the breakdown of the blood-retinal barrier 46 . Several mechanisms are believed to underlie these actions, i.e. VEGF directly acts on the permeability of intact blood vessels and promotes infl ux of infl ammatory cells, thus leading to endothelial cell apoptosis in retinal vasculature 47 . Four VEGF-binding agents are currently used for ocular diseases: pegaptanib, bevacizumab (off -label), ranibizumab and afl ibercept.
Pegaptanib (Macugen®; Eyetech Pharmaceuticals, Inc. and Pfi zer Inc., New York, USA) is a pegylated aptamer that targets the VEGF 165 isoform. In 2004, it was approved by the FDA for the treatment of wet age-related macular degeneration and was the fi rst anti-VEGF agent reported to have effi cacy in the treatment of DME. Th e Macugen Diabetic Retinopathy Study Group conducted a phase II RCT of pegaptanib for fovea-involving DME 48 . Th e pegaptanibtreated eyes had better VA, greater reduction in CRT and less need for laser compared to the sham group. More recently, data from phase II/III RCT showed that pegaptanib was associated with improved VA in patients with DME for up to 2 years 49 . However, Pfi zer pharmaceuticals are no longer pursuing further studies of pegaptanib in DME.
Bevacizumab (Avastin®; Genentech, South San Francisco, CA, USA) is a full-length humanized monoclonal G1 antibody that inactivates all VEGF isoforms and is indicated for systemic use as an adjunct cancer chemotherapeutic agent 50 . In ophthalmology, bevacizumab has emerged as a therapeutic agent for retinal vascular diseases 51 and has been used as an off -label agent in a number of ocular diseases, including DR and DME 52 . Th ere have been a number of published trials with short follow up and using different treatment doses/regimens and diff erent comparison groups that investigated the eff ect of bevacizumab in DME 53 . Th e BOLT study compared intravitreal bevacizumab to focal laser and found superior VA results at 12 months (+8 vs. -0.5 letters), 5.1 times greater odds of gaining >10 letters, and a decrease in CRT (130 μm vs. 68 μm) in bevacizumab versus laser group 54 . Ranibizumab (Lucentis®; Genentech, South San Francisco, CA, USA) is a humanized antibody fragment directed at all isoforms of VEGF-A and is fabricated specifi cally for intravitreal use. FDA approved ranibizumab for the treatment of DME in 2012 and for the treatment of DR in February 2015. Evidence for DME treatment with ranibizumab is based on data from phase II and III RTCs, including the Safety and Effi cacy of Ranibizumab in DME (RESOLVE) 55 ; Ranibizumab for Edema of the mAcula in Diabetes (READ-2) 56 ; Core Study to Assess the Effi cacy and Safety of Ranibizumab Intravitreal Injections (RESTORE) 57 ; Diabetic Retinopathy Clinical Research Network (DRCR.net) Protocol I 58 and Study of Ranibizumab Injection in Subjects with CS-DME Secondary to Diabetes (RISE and RIDE) 59 . Afl ibercept (Eylea®; Bayer Healthcare Pharmaceuticals, Berlin, Germany) is a 115-kDA recombinant fusion protein consisting of the VEGF binding domains of human VEGF receptors 1 and 2 fused to the Fc domain of human immunoglobulin-G1 60 . Animal studies demonstrated intravitreal afl ibercept to have theoretic advantages over bevacizumab and ranibizumab, including longer half-life in the eye and higher binding affi nity to VEGF-A 61 . In addition, the fusion protein binds PGF 1 and 2, which have been shown to contribute to excessive vascular permeability and retinal neovascularization 62 . In 2014, FDA approved afl ibercept for the treatment of DME and in March 2015 for the treatment of DR in patients with DME. Evidence for DME treatment with afl ibercept is based on data from phase II and III RCTs, including the DME and VEGF Trap-Eye: INvestigation of Clinical Impact (DA VINCI) study 63 ; Study of VEGF Trap-Eye in Vision Impairment due to DME (VIV-ID DME ) and Intravitreal Administration of VEGF Trap-Eye in Patients with DME (VISTA DME ) 64 . More recently, data from the DRCR.net Protocol T showed that intravitreal afl ibercept, bevacizumab and ranibizumab improved vision in eyes with center-involved DME, but the relative eff ect depended on baseline VA. When the initial VA loss was mild, there were no differences among study groups. At worse levels of initial VA, afl ibercept was more eff ective in improving vision 65 .
All intravitreal anti-VEGF agents were generally well tolerated in all studies. Th e most commonly reported ocular serious adverse events were endophthalmitis and increased intraocular pressure. Systemic adverse events in patients having received anti-VEGF for DME occurred at rates equal to those in patients that received laser treatment or sham injection. Th e incidence of cardiovascular events and arterial thromboembolism reported in these studies was low, possibly because high-risk patients were excluded.
Surgical vitrectomy as a novel treatment of DME is indicated in widespread/diff use DME that is refractory to laser and intravitreal treatment, and is caused by vitreous traction in association with visual impairment. In their study of vitrectomy for DME, Haller et al. found improvement of VA by ≥10 letters in 38%, reduction in central subfi eld thickness to <250 μm in 50% of patients, and reduction of thickness of ≥50% in most of the eyes 66 .
Guidelines for Treatment of DME
Treatment of DME depends on VA and location/ extent of macular thickening based on optical coherence tomography (OCT) scans, and the guidelines provide paradigms based on the classifi cation scale, current evidence and consensus of opinion [67] [68] [69] . According to the International Clinical Classifi cation Scale, DME is divided into no center-involving DME and center-involving DME, confi rmed with OCT, which is not explained by thickening from an epiretinal membrane 70 . Visual acuity 6/9 (0.7) and OCT central subfi eld thickness >250 μm are crucial when choosing a treatment option, also referring to the patient's individual circumstances.
No center-involving DME should be treated with a modifi ed ETDRS focal/grid laser photocoagulation according to the following recommendations 31 : -direct focal photocoagulation of leaking microaneurysms 500 to 3000 μm from fovea with 50-μm spot size, duration 0.05-0.1 s and intensity to achieve grayish reaction, and -grid photocoagulation of areas of retinal thickening from 500 to 3000 μm superiorly and inferiorly and to 3500 μm temporally with barely visible 200-300 burns size 50-100 μm, duration 0.05-0.1 s and a space of two burns width apart.
Th e same treatment should be considered in center-involving DME with VA >6/9 (0.7), central subfi eld thickness <250 μm and microaneurysms located in areas accessible to laser. After the macular laser, 3-to 4-month follow up is recommended as long as no other features are present that require other treatment option or more regular follow up.
Center-involving DME with VA >6/9 (0.7) and central subfi eld thickness >250 μm should be treated with intravitreal anti-VEGF agents with or without macular laser. For phakic eyes unresponsive to these treatments, intravitreal dexamethasone implant may be considered, bearing in mind the potential side effects. Th e same treatment should be undertaken in center-involving DME with VA 6/9-6/10 (0.7 to 0.6) or worse and central subfi eld thickness >250 μm. For pseudophakic eyes, IVTA or dexamethasone implant with or without laser may also be considered. Anti-VEGF treatment regimen includes initial loading phase of monthly injections for 4-6 months, followed by PRN phase with continued treatment until the macula is dry or until there is no further improvement. Monthly follow up of patients undergoing anti-VEGF treatment with VA assessment and OCT scan is required to decide on re-treatments. For patients undergoing intravitreal steroid treatment, regular monitoring of intraocular pressure is also required. If the patient has been stable off treatment for several monthly assessments, the period between follow up appointments may be increased gradually to a maximum of 3-4 months as long as there are no other features requiring more frequent follow up. Center-involving DME with VA <6/12 (0.5) and central subfi eld thickness >250 μm should be observed, especially if longstanding and no response to previous laser, or if there is huge macular ischemia. Otherwise, anti-VEGF or steroid treatment may be considered after careful consultation. Center-involving DME with vitreomacular traction is an indication for vitrectomy with or without intravitreal anti-VEGF or steroid treatment.
Conclusion
Diabetic macular edema is a signifi cant public health challenge. Many patients are undiagnosed and untreated, and even those treated with standard laser therapy may respond poorly and progressively lose vi-sion. Although laser photocoagulation has long been the primary treatment for preventing blindness in patients with DME, treatment goals should now aim to restore impaired vision, prevent further vision loss and improve visual function. Better knowledge of the pathophysiology of DME and recent RCTs suggest that these goals can be achieved using novel treatment options, intravitreal anti-VEGF and corticosteroidbased therapy, with a well-documented tolerable safety profi le. As a result of these recent data, the intravitreal anti-VEGF agents and steroids are suggested as fi rstline treatment in place of laser photocoagulation in DME causing vision loss. New guidelines recommend intravitreal treatment as the treatment of choice for patients with center-involving DME and moderate visual impairment. Patients with no center-involving DME and mild visual impairment should be treated with modifi ed ETDRS focal/grid laser photocoagulation and closely observed. Vitrectomy is the treatment of choice for patients with a tractional component of DME. Undoubtedly, in the future patients might need various combinations of these therapies to obtain the best outcome; thus, many studies are already running to address this goal. 
